Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease
September 19, 2022 08:00 ET
|
Gain Therapeutics, Inc.
Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills Results Presented at the International Congress of Parkinson’s Disease...
Gain Therapeutics to Present Data at Upcoming Medical Meetings
September 08, 2022 08:00 ET
|
Gain Therapeutics, Inc.
Presenting Preclinical Data at 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain Upcoming Presentation on GBA-PD program at First International Symposium...
Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update
August 08, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference
August 04, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics to Participate at the Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update
May 16, 2022 16:05 ET
|
Gain Therapeutics, Inc.
Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. ...
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium
May 11, 2022 09:30 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., May 11, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress
May 06, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., May 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company applying its proprietary computational discovery platform...